Skip to main content
SpringerLink
Log in

Konzepte und Ausblick für Patienten über 60 Jahre

Zukunft gestalten - Behandlung von älteren Patienten mit Hodgkin-Lymphom

  • Hämatologie
  • Fortbildung
  • Published:
Im Fokus Onkologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

© modifiziert nach ghsg.org/therapie

Abb. 2
Abb. 3

© modifiziert nach [10]

Literatur

  1. Sjoberg J et al. Progress in Hodgkin lymphoma: a population-based study on patients diagnosed in Sweden from 1973-2009. Blood. 2012;26;119(4):990-6

  2. Proctor SJ et al. Evaluation of treatment outcome in 175 patients with Hodgkin lymphoma aged 60 years or over: the SHIELD study. Blood. 2012;119(25):6005-15

  3. Engert A et al. Hodgkin's lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin's Study Group. J Clin Oncol. 2005;23(22):5052-60

  4. Enblad G et al. Treatment outcome in Hodgkin's disease in patients above the age of 60: a population-based study. Ann Oncol. 1991;2(4):297-302

  5. Wongso D et al. Treatment-related mortality in patients with advanced-stage hodgkin lymphoma: an analysis of the german hodgkin study group. J Clin Oncol. 2013;31(22):2819-24

  6. Evens AM et al. A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era. Blood. 2012;119(3):692-5

  7. Böll B et al. ABVD in Older Patients With Early-Stage Hodgkin Lymphoma Treated Within the German Hodgkin Study Group HD10 and HD11 Trials. J Clin Oncol. 2013;31(12):1522-9

  8. Borchmann S et al. Hodgkin lymphoma in elderly patients. Curr Opin Oncol. 2018;30(5):308-16

  9. Engert A. Treatment of elderly Hodgkin lymphoma patients. Hematol Oncol 2019;37(Suppl 1):92-4

  10. Böll B et al. Relapsed Hodgkin Lymphoma in Older Patients: A Comprehensive Analysis From the German Hodgkin Study Group. J Clin Oncol. 2013;31(35):4431-7

  11. Puig N et al. High-dose chemotherapy and auto-SCT in elderly patients with Hodgkin's lymphoma. Bone Marrow Transplant. 2011;46(10):1339-44

  12. Santoro A et al. Gemcitabine in the Treatment of Refractory Hodgkin's Disease: Results of a Multicenter Phase II Study. J Clin Oncol. 2000;18(13):2615-9

  13. Younes A et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol. 2012;30(18):2183-9

  14. Forero-Torres A et al. Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older. Blood. 2015;126(26):2798-804

  15. Connors JM et al. Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma. N Engl J Med. 2018;378(4):331-44

  16. Evens AM et al. Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblastine, and Dacarbazine Chemotherapy for Older Patients With Untreated Classical Hodgkin Lymphoma. J Clin Oncol. 2018;36(30):3015-22

  17. Böll B et al. B-CAP (Brentuximab Vedotin, Cyclophosphamide, Doxorubicin and predniso(lo)Ne) in older patients with advanced-stage hodgkin lymphoma: results of a phase II intergroup trial By the German Hodgkin study group (GHSG) and the Nordic Lymphoma group (NLG). Oncol Res Treat. 2019;42(suppl 4):Abstr V609

  18. Armand P et al. Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure. J Clin Oncol. 2016;34(31):3733-9

  19. Kasamon YL et al. FDA Approval Summary: Nivolumab for the Treatment of Relapsed or Progressive Classical Hodgkin Lymphoma. Oncologist. 2017;22(5):585-91

  20. Armand P et al. Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial. J Clin Oncol. 2018;36(14):1428-39

Download references

Author information

Authors and Affiliations

  1. Klinik für Inn. Medizin Univ. Klinikum Köln, Kerpener Str. 62, 50937, Köln, Germany

    Boris Böll

  2. Universitätsklinikum Köln, Kerpener Straße 62, Köln, Germany

    Jesko Momotow

Authors
  1. Boris Böll
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jesko Momotow
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Boris Böll.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Böll, B., Momotow, J. Zukunft gestalten - Behandlung von älteren Patienten mit Hodgkin-Lymphom. Im Fokus Onkologie 23, 15–18 (2020). https://doi.org/10.1007/s15015-020-2423-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15015-020-2423-1

Search

Navigation